EXPERIENCE OF APPLICATION OF THE FIRST REPRESENTATIVE OF CLASS ARNI (ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR) SACUBITRIL/VALSARTAN IN PATIENTS WITH CARDIOPULMONIAL PATHOLOGY

The article is devoted to a new drug- the first ARNI class (Angiotensin Receptor-Neprilysin Inhibitor) for the treatment of heart failure - a combination of sacubi tryl and valsartan, recently appeared on the pharmaceutical market, andalready included in the European recommendations in view of proven efficacy and safety. The article deals with the experience of using the combination of sacubitryl/valsartan in patients with cardiopulmonary pathology. The purpose of this article is to summarize the main steps leading to the development of a new treatment regimen for patients with severe heart failure. The article covers the history of the discovery of renin-angiotensin-aldosterone and natriuretic systems, as well as the mechanisms of their interaction. The questions of synthesis, secretion, clearance of vasoactive substances regulating these systems are considered. The diagnostic and prognostic significance of drugs aimed at various links of pathogenesis in patients with chronic heart failure was analyzed. Considered both positive and negative results of clinical studies, which in the end led to the creation of a new drug LCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor. The results of the clinical study PARADIGM-HF were evaluated, and the practical and clinical significance of the possibility of using LCZ696 in different categories of patients was determined (bibliography: 11 refs).

chronic insufficiency, chronic obstructive pulmonary, neprilysin, renin-angiotensin-aldosterone system, sacubitryl, valsartan